ALGYL GGP
Preparation and activation
Optimisation of the intra-articular environment (HA viscosupplementation), activation of cartilage metabolism and support of proteoglycan synthesis.
ALGYL GGP · flagship product
Beyond viscosupplementation.
The first intra-articular injection combining four bioactive components in a patented formulation, targeting multiple pathogenetic processes of gonarthrosis at once — in a single 2 mL syringe.
200,000+applications with no serious AE*
111patients in the prospective study
III · CEclass III medical device
1,200 kDaHA molecular weight
Composition
Four components, one injection, documented synergy.
Traditional HA addresses only viscosupplementation. Yet osteoarthritis is multifactorial. Each component of ALGYL GGP targets a different pathogenetic factor — and their effects complement one another.
Hyaluronic acid
40 mg / 2 ml · 1,200 kDa
Synovial-fluid viscoelasticity, analgesia, chondrocyte stimulation.
N-acetylglucosamine
60 mg / 2 ml
Stimulates proteoglycan and HA synthesis, inhibits matrix metalloproteinases.
Glycine
40 mg / 2 ml
Essential for the stable collagen triple helix; antioxidant and anti-inflammatory effect.
Proline
30 mg / 2 ml
Key to collagen synthesis in chondrocytes, supports cartilage regeneration.
HA: 1,200 kDa (French origin)
Volume: 2 mL pre-filled syringe
Suitable needle: 18–22G
Classification: Class III MD · CE
Patent: WO 2024/080954A1
Mechanism of action
Faster HA onset, sequential engagement of the other components.
Hyaluronic acid is only one part of the product — the other components extend the formulation toward a longer, more comprehensive reparative effect.
- Hyaluronic acid — rapid onset linked to joint viscoelastic milieu.
- N-acetylglucosamine — adds a layer linked to matrix and proteoglycans.
- Glycine and proline — amino acids involved in collagen synthesis; support long-term cartilage repair.
Formulation timing chart
Schematic representation of the temporal interplay of the formulation's components. hyaluronic acid N-acetylglucosamine glycine + proline overall ALGYL GGP effect
Clinical study
Prospective randomized blinded clinical study in 111 patients with gonarthrosis.
Three regimens (HA / HA + proline / full ALGYL GGP combination) evaluated with WOMAC, Lequesne and VAS at week 12.
Study design
111 patients, grade II–III gonarthrosis (Kellgren-Lawrence), aged 40–80 years.
n=35HA alone
n=29HA + L-proline
n=47ALGYL GGP (4 components)
2 · 8 · 12follow-up weeks
Lower values indicate a better outcome. The charts reproduce data from the clinical study (Kaval B., 2025). The full methodology and the statistical evaluation are given in the clinical summary and in the original publication.
→
At week 12 the group with the four-component formulation reached statistically significantly better WOMAC, VAS and Lequesne index values than both comparator groups (p<0.001 for WOMAC and VAS, p<0.05 for Lequesne). Improvement continued between weeks 8 and 12, whereas in both comparator groups some patients deteriorated again during this period.
▣
Efficacy and safety — laboratory study and clinical practice
A laboratory study demonstrated that, in the treatment of knee osteoarthritis, ALGYL GGP is significantly more effective than single-component hyaluronic acid or saline and leads to regression of degenerative cartilage changes (Gök O., 2024). In orthopaedic practice, ALGYL GGP has been used in more than 200,000 applications in gonarthrosis and has proved effective and safe, with a long-lasting effect. The safety report confirms that no adverse events occurred with administration of the product, such as joint pain or swelling, injection-site reactions or other complications.
Safety profile
200,000+
applications in orthopaedic practice without reported serious adverse events.*
- Only AE observed in the study: transient post-injection pain, comparable across groups.
- Applied under aseptic conditions by a physician.
- Contraindications and full information always per the approved IFU.
Formulation
Four components in a single 2 mL syringe.
Sodium hyaluronate, N-acetylglucosamine, glycine and L-proline in one sterile pre-filled syringe for intra-articular use.
Sodium hyaluronateN-acetylglucosamineGlycineL-proline
Physician experience
Comment on the clinical study.
„The four-component combination of biogenic substances is a rational extension of the intra-articular approach in gonarthrosis.“
Prof. Dr. habil. Pavel Dufek has long specialized in orthopaedics, trauma surgery and sports medicine. This expert comment reflects the author's clinical view — it does not replace the clinical-study results or the current IFU.
Prof. Dr. habil. Pavel DufekOrthopaedics · trauma surgery · sports medicine
Technical specification
Technical and mechanical parameters.
Appearanceclear transparent yellowish viscous gel
Particle size< 0.02 µm
Density1.010–1.030 g/cm³
Colour≤ 5.0 Pt-Co
Turbidity< 1.0 NTU
Osmolality200–400 mOsm/kg
Bacterial endotoxin test≤ 1 EU/ml
Viscosity5–50 000 cp
pH6.5–7.5
Intended purpose and indications
Wording per currently published IFU (rev. 03/2025).
The medical device ALGYL GGP is intended for the treatment of symptoms of joint disorders such as osteoarthritis. It is indicated to increase viscoelasticity and for cartilage-tissue reconstruction or to supplement synovial fluid in joints.
Application procedure
Application in orthopaedic practice.
The specific choice, dosage and frequency are always determined by the treating physician based on the patient's condition and current IFU.
- ALGYL GGP is administered once every 6 months.
- Depending on disease severity, the effect of the intra-articular injection lasts approximately 6 months. If needed, a second dose may be given.
- For joint effusion, aspiration of exudate, rest, ice packs and/or intra-articular corticosteroid administration are recommended. ALGYL GGP application follows after 2–3 days.
- The intra-articular injection should be given by an orthopaedist.
- Use a suitable 18–22G needle for application.
Complete information on use, contraindications, warnings and possible adverse events is provided in the current instructions for use.
Sequential protocol
ALGYL GGP opens a two-step sequence.
A professional proposal for a combined approach that respects the individual phases of joint tissue repair. The approximate interval between the main steps is 2–3 weeks.
ALGYL COLL
Structural support
Continued viscosupplementation and recombinant collagen as a structural component for regeneration of the extracellular matrix.
The scheme is a professional proposal for a combined approach, not a universal treatment algorithm.
View the whole scheme
Downloads and contact
ALGYL GGP documentation
Instructions PIL / IFU
PIL / IFU — approved versionRevision 03/2025 · Class III medical device · CE
For healthcare professionals
Would you like ALGYL GGP in your practice?
We will put you in touch with the inPHARM specialist representative for your region — with complete documentation, clinical evidence and a tailored offer.
I’m interested — contact a representative